Research Methodologies Followed in This Study:
In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the orthopedic braces and supports market study.
The human organoids market comprises several stakeholders such as Manufacturers of human organoid products, Healthcare service providers, Manufacturers of pharmaceutical products, Pharmaceutical and biotechnology companies, Clinical research organizations (CROs), Clinical testing laboratories, Public and private research organizations, Research laboratories and academic institutes, Market research and consulting firms The demand side of this market is characterized by the increasing incidence of transplants and technological advancements, and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Download PDF Brochure@
Expected Growth Global Revenue:
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.
Major Growth Boosting Factors:
The global human organoids market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, rising incidence of transplants, and increased funding and public-private investments are key factors driving the growth of the human organoids market.
Restraint: Issues related to the incorporation of organoids into existing workflows
The lack of infrastructure for 3D cell culture research is significantly limiting the overall growth of the organoids market. The availability of the necessary equipment to use advanced techniques is one of the prerequisites for conducting 3D cell culture-based research. Moreover, various technical challenges are involved in incorporating organoids into existing research workflows as the manufacturing of organoids is capital- and time-intensive. Owing to this, the adoption of organoids in ongoing drug screening and drug discovery activities is limited. This is a major issue as the ongoing drug screening and drug discovery processes will take a long time (up to a few years) to complete.
# In 2020, BIOIVT (US) partnered with upcyte technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
# In 2019, Hurel and Cyprotex came into partnership which enabled Cyprotex to independently validate the HµREL multi-donor coculture model for clearance studies.
# In 2019, Organovo collaborated with MCRI and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatment for kidney diseases.
# In 2018, Absolute Antibody merged with Kerafast to increase access to unique reagents.
Request Sample Pages@
Geographical Growth Scenario:
North America is the largest regional market for Human Organoids
North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers.
Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.